Latest News and Press Releases

– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part...

World-renowned neuroscientist, Dean of the Icahn School of Medicine at Mount Sinai, and longtime BPGbio’s SAB member, appointed Chair of the SAB, succeeding Chas Bountra, Ph.D., who recently...

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies...

Cross Keys Capital acted as the exclusive advisor to the Neurology Group of Bergen County in its partnership with Privia Health.

Vertero doses first Parkinson’s patient in Phase 1b study of VT-5006, a gut-selective therapy targeting disease progression.

– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –  – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for...

CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in...

LeonaBio, Inc. (NASDAQ: LONA), announced the appointment of Fred Callori, J.D., Natalie Holles, and Peter Silverman, J.D. to its Board of Directors.

MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...